Panic Disorders Market Analysis Highlights Growth To $14.99 Billion By 2030 At 6.3% CAGR

The growing awareness around mental health and the increasing prevalence of anxiety-related conditions have brought significant attention to the panic disorders market. With advancements in treatment options and expanding healthcare infrastructure, this market is expected to witness considerable growth in the coming years. Let's explore the current market size, key players, emerging trends, and segmentation within the panic disorders industry.

Projected Growth and Market Size of the Panic Disorders Market
The panic disorders market is on track for substantial expansion, anticipated to reach a valuation of $15 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 6.3%. Key factors contributing to this upward trajectory include a rising number of anxiety and panic disorder cases, broader adoption of telepsychiatry services, innovations in virtual reality and neurofeedback therapies, and the broadening availability of online pharmacy and hospital distribution networks. Additionally, demand for tailored mental health treatment plans is expected to further propel the market forward. Important trends driving the market include increased use of telepsychiatry and mobile mental wellness apps, integration of virtual reality for anxiety treatments, growing application of biofeedback and neurofeedback techniques, personalized medication strategies, and the expansion of mental health facilities.

The panic disorders market size has grown strongly in recent years. It will grow from $11.15 billion in 2025 to $11.73 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to limited awareness of panic disorders, reliance on traditional in-person therapy, high cost of medications, fragmented mental healthcare infrastructure, low adoption of digital therapy tools.

Download a free sample of the panic disorders market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13191&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Companies Leading the Panic Disorders Market
A range of prominent pharmaceutical and biotech companies have a strong presence in the panic disorders space. Notable market players include F. Hoffmann-La Roche Ltd, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd, Mylan N.V., Pfizer Inc, Sun Pharmaceutical Industries Ltd, H. Lundbeck A/S, Neurocrine Biosciences Inc, Neuraxpharm, Actavis Plc, Sumitomo Pharma Co Ltd, LIFECARE NEURO PRODUCTS LTD, Merck & Co Inc, Johnson & Johnson, Novartis AG, and Otsuka Pharmaceutical Co Ltd.

Significant Industry Moves Strengthening Market Position
In February 2023, Vistagen Therapeutics Inc., a clinical-stage biopharmaceutical company based in the US, completed the acquisition of Pherin Pharmaceuticals Inc. Although the financial details were not disclosed, this acquisition positions Vistagen to develop and commercialize innovative therapies for depression and anxiety disorders, including panic disorders. Pherin Pharmaceuticals is well-known for its focus on drug development tailored to panic disorder treatments. This strategic move is anticipated to enhance the commercial potential of Vistagen's existing and future drug candidates.

View the full panic disorders market report:
https://www.thebusinessresearchcompany.com/report/panic-disorders-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping Treatment Approaches in Panic Disorders
Pharmaceutical companies are actively investing in the development of advanced formulations such as extended-release capsules to maintain and strengthen their market share. These medications release therapeutic agents gradually over a specified timeframe, usually 12 to 24 hours, which is particularly beneficial for conditions requiring continuous medication.
For example, in May 2023, Granules India Ltd., headquartered in India, received approval from the US Food & Drug Administration (USFDA) for an abbreviated new drug application (ANDA) for venlafaxine hydrochloride extended-release capsules. This drug has shown bioequivalence to the reference product Effexor XR Extended-Release Capsules, produced by Upjohn US 2 LLC. Venlafaxine HCl extended-release capsules are prescribed to treat generalized anxiety disorder (GAD), major depressive disorder (MDD), panic disorder (PD), and social anxiety disorder (SAD). The medication works by increasing serotonin and norepinephrine levels in the brain, usually beginning with a daily dose of 75 mg that may be adjusted by healthcare providers according to patient needs.

Detailed Segmentation Covered in the Panic Disorders Market Report
The panic disorders market is analyzed based on several important segments:

By Treatment Type:
- Pharmacotherapies
- Psychotherapeutic Interventions
- Digital or Tech-Enabled Therapies

By Disorder Type:
- Panic Disorder Without Agoraphobia
- Panic Disorder With Agoraphobia
- Mild Panic Disorder
- Moderate Panic Disorder
- Severe Panic Disorder
- Panic Disorder With Comorbidities

By Age Group:
- Children and Adolescents
- Adults
- Elderly

By End User:
- Hospitals
- Specialty Mental Health Clinics
- Primary Care Clinics
- Telehealth and Digital Platforms
- Home Healthcare Services

Subsegments include:
Pharmacotherapies such as antidepressants, benzodiazepines, and beta-blockers; psychotherapeutic interventions like cognitive behavioral therapy (CBT), exposure therapy, psychodynamic therapy, and group and family therapy; and digital therapies including mental health apps, telepsychiatry or teletherapy services, and virtual CBT programs.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.